LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel: Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2

    Kim, Chulwoo / Kim, Jae-Deog / Seo, Sang-Uk

    journal of microbiology. 2022 Mar., v. 60, no. 3

    2022  

    Abstract: The global spread of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has provoked an urgent need for prophylactic measures. Several innovative vaccine platforms have been introduced and billions ... ...

    Abstract The global spread of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has provoked an urgent need for prophylactic measures. Several innovative vaccine platforms have been introduced and billions of vaccine doses have been administered worldwide. To enable the creation of safer and more effective vaccines, additional platforms are under development. These include the use of nanoparticle (NP) and virus-like particle (VLP) technology. NP vaccines utilize self-assembling scaffold structures designed to load the entire spike protein or receptor-binding domain of SARS-CoV-2 in a trimeric configuration. In contrast, VLP vaccines are genetically modified recombinant viruses that are considered safe, as they are generally replication-defective. Furthermore, VLPs have indigenous immunogenic potential due to their microbial origin. Importantly, NP and VLP vaccines have shown stronger immunogenicity with greater protection by mimicking the physicochemical characteristics of SARS-CoV-2. The study of NP- and VLP-based coronavirus vaccines will help ensure the development of rapid-response technology against SARS-CoV-2 variants and future coronavirus pandemics.
    Schlagwörter COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; immunogenicity ; virus-like particle vaccines
    Sprache Englisch
    Erscheinungsverlauf 2022-03
    Umfang p. 335-346.
    Erscheinungsort The Microbiological Society of Korea
    Dokumenttyp Artikel
    Anmerkung Review
    ZDB-ID 2012399-1
    ISSN 1225-8873
    ISSN 1225-8873
    DOI 10.1007/s12275-022-1608-z
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2.

    Kim, Chulwoo / Kim, Jae-Deog / Seo, Sang-Uk

    Journal of microbiology (Seoul, Korea)

    2022  Band 60, Heft 3, Seite(n) 335–346

    Abstract: The global spread of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has provoked an urgent need for prophylactic measures. Several innovative vaccine platforms have been introduced and billions ... ...

    Abstract The global spread of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has provoked an urgent need for prophylactic measures. Several innovative vaccine platforms have been introduced and billions of vaccine doses have been administered worldwide. To enable the creation of safer and more effective vaccines, additional platforms are under development. These include the use of nanoparticle (NP) and virus-like particle (VLP) technology. NP vaccines utilize self-assembling scaffold structures designed to load the entire spike protein or receptor-binding domain of SARS-CoV-2 in a trimeric configuration. In contrast, VLP vaccines are genetically modified recombinant viruses that are considered safe, as they are generally replication-defective. Furthermore, VLPs have indigenous immunogenic potential due to their microbial origin. Importantly, NP and VLP vaccines have shown stronger immunogenicity with greater protection by mimicking the physicochemical characteristics of SARS-CoV-2. The study of NP- and VLP-based coronavirus vaccines will help ensure the development of rapid-response technology against SARS-CoV-2 variants and future coronavirus pandemics.
    Mesh-Begriff(e) Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Nanoparticles ; SARS-CoV-2 ; Vaccines, Virus-Like Particle
    Chemische Substanzen Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Vaccines, Virus-Like Particle
    Sprache Englisch
    Erscheinungsdatum 2022-01-28
    Erscheinungsland Korea (South)
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2012399-1
    ISSN 1976-3794 ; 1225-8873
    ISSN (online) 1976-3794
    ISSN 1225-8873
    DOI 10.1007/s12275-022-1608-z
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus.

    Kim, Jae-Deog / Lee, Ah-Ra / Moon, Dah-Hyun / Chung, Young-Uk / Hong, Su-Yeon / Cho, Hyo Je / Kang, Tae Hyun / Jang, Yo Han / Sohn, Myung Hyun / Seong, Baik-Lin / Seo, Sang-Uk

    Emerging microbes & infections

    2024  Band 13, Heft 1, Seite(n) 2343910

    Abstract: Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V ( ... ...

    Abstract Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V (GV) JEV poses a challenge as current vaccines are genotype III (GIII)-based and provide suboptimal protection. Given the isolation of GV JEVs from Malaysia, China, and the Republic of Korea, there is a concern about the potential for a broader outbreak. Under the hypothesis that a GV-based vaccine is necessary for effective defense against GV JEV, we developed a pentameric recombinant antigen using cholera toxin B as a scaffold and mucosal adjuvant, which was conjugated with the E protein domain III of GV by genetic fusion. This GV-based vaccine antigen induced a more effective immune response in mice against GV JEV isolates compared to GIII-based antigen and efficiently protected animals from lethal challenges. Furthermore, a bivalent vaccine approach, inoculating simultaneously with GIII- and GV-based antigens, showed protective efficacy against both GIII and GV JEVs. This strategy presents a promising avenue for comprehensive protection in regions facing the threat of diverse JEV genotypes, including both prevalent GIII and GI as well as emerging GV strains.
    Mesh-Begriff(e) Encephalitis Virus, Japanese/genetics ; Encephalitis Virus, Japanese/immunology ; Encephalitis Virus, Japanese/classification ; Animals ; Genotype ; Encephalitis, Japanese/prevention & control ; Encephalitis, Japanese/immunology ; Encephalitis, Japanese/virology ; Japanese Encephalitis Vaccines/immunology ; Japanese Encephalitis Vaccines/administration & dosage ; Japanese Encephalitis Vaccines/genetics ; Mice ; Antibodies, Viral/immunology ; Antibodies, Viral/blood ; Humans ; Mice, Inbred BALB C ; Female ; Antigens, Viral/immunology ; Antigens, Viral/genetics ; Vaccine Efficacy ; Cholera Toxin/genetics ; Cholera Toxin/immunology
    Chemische Substanzen Japanese Encephalitis Vaccines ; Antibodies, Viral ; Antigens, Viral ; Cholera Toxin (9012-63-9)
    Sprache Englisch
    Erscheinungsdatum 2024-04-29
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2681359-2
    ISSN 2222-1751 ; 2222-1751
    ISSN (online) 2222-1751
    ISSN 2222-1751
    DOI 10.1080/22221751.2024.2343910
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Development of Combination Vaccine Conferring Optimal Protection against Six Pore-Forming Toxins of Staphylococcus aureus.

    Zhang, QingFeng / Jiang, TingTing / Mao, Xinrui / Kim, Jae Deog / Ahn, Dong Ho / Jung, Yunjin / Bae, Taeok / Lee, Bok Luel

    Infection and immunity

    2021  Band 89, Heft 10, Seite(n) e0034221

    Abstract: In the Gram-positive pathogen Staphylococcus aureus, pore-forming toxins (PFTs), such as leukocidins and hemolysins, play prominent roles in staphylococcal pathogenesis by killing host immune cells and red blood cells (RBCs). However, it remains unknown ... ...

    Abstract In the Gram-positive pathogen Staphylococcus aureus, pore-forming toxins (PFTs), such as leukocidins and hemolysins, play prominent roles in staphylococcal pathogenesis by killing host immune cells and red blood cells (RBCs). However, it remains unknown which combination of toxin antigens would induce the broadest protective immune response against those toxins. In this study, by targeting six major staphylococcal PFTs (i.e., gamma-hemolysin AB [HlgAB], gamma-hemolysin CB [HlgCB], leukocidin AB [LukAB], leukocidin ED [LukED], Panton-Valentine leukocidin [LukSF-PV], and alpha-hemolysin [Hla]), we generated 10 recombinant toxins or toxin subunits, 3 toxoids, and their rabbit antibodies. Using the cytolytic assay for RBCs and polymorphonuclear cells (PMNs), we determined the best combination of toxin antibodies conferring the broadest protection against those staphylococcal PFTs. Although anti-HlgA IgG (HlgA-IgG) showed low cross-reactivity to other toxin components, it was essential to protect rabbit and human RBCs and human PMNs. For the protection of rabbit RBCs, Hla
    Mesh-Begriff(e) Animals ; Bacterial Proteins/immunology ; Bacterial Toxins/immunology ; Cross Reactions/immunology ; Erythrocytes/immunology ; Erythrocytes/microbiology ; Exotoxins/immunology ; Hemolysin Proteins/immunology ; Humans ; Immunization/methods ; Leukocidins/immunology ; Neutrophils/immunology ; Neutrophils/microbiology ; Rabbits ; Staphylococcal Infections/immunology ; Staphylococcal Infections/microbiology ; Staphylococcus aureus/immunology ; Toxoids/immunology ; Vaccines, Combined/immunology
    Chemische Substanzen Bacterial Proteins ; Bacterial Toxins ; Exotoxins ; Hemolysin Proteins ; Leukocidins ; Panton-Valentine leukocidin ; Toxoids ; Vaccines, Combined
    Sprache Englisch
    Erscheinungsdatum 2021-07-06
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 218698-6
    ISSN 1098-5522 ; 0019-9567
    ISSN (online) 1098-5522
    ISSN 0019-9567
    DOI 10.1128/IAI.00342-21
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Cloning, Expression, and Characterization of a Thermotolerant β-agarase from Simiduia sp. SH-4

    Kim, Jae-Deog / Dong-Geun Lee / Sang-Hyeon Lee

    Biotechnology and bioprocess engineering. 2018 Sept., v. 23, no. 5

    2018  

    Abstract: The gene coding for a thermotolerant β-agarase from an isolated Simiduia sp. SH-4 was cloned, recombinantly expressed, and characterized after purification. This gene was sequenced after cassette mediated polymerase chain reaction and composed of an open ...

    Abstract The gene coding for a thermotolerant β-agarase from an isolated Simiduia sp. SH-4 was cloned, recombinantly expressed, and characterized after purification. This gene was sequenced after cassette mediated polymerase chain reaction and composed of an open reading frame of 1,809 base pairs, encoding a protein of 66.2 kilodaltons comprising of 602 amino acid residues. The amino acids sequence showed 74% homology with β-agarase of Simiduia agarivorans. A new β-agarase gene corresponding to mature protein of 577 amino acids was recombinantly expressed and purified by chitin bead column to homogeneity. The maximal specific activity was 505.07 U/mg at 50oC in Tris/HCl (pH 6.0) buffer. Recombinant β-agarase hydrolyzed agar into neoagarotetraose (57%) and neoagarohexaose (43%). It generated products from melted and non-melted powder agar and agarose at 30-50oC, meaning cheap agar materials could be used with energy- and costsavings. Thus, recombinant β-agarase could be used for industrial production of neoagarotetraose and neoagarohexaose.
    Schlagwörter agar ; agarose ; amino acid sequences ; amino acids ; beta-agarase ; chitin ; genes ; heat tolerance ; hydrochloric acid ; hydrolysis ; open reading frames ; pH ; polymerase chain reaction
    Sprache Englisch
    Erscheinungsverlauf 2018-09
    Umfang p. 525-531.
    Erscheinungsort The Korean Society for Biotechnology and Bioengineering
    Dokumenttyp Artikel
    ZDB-ID 2125481-3
    ISSN 1976-3816 ; 1226-8372
    ISSN (online) 1976-3816
    ISSN 1226-8372
    DOI 10.1007/s12257-018-0072-4
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: In Staphylococcus aureus, the Particulate State of the Cell Envelope Is Required for the Efficient Induction of Host Defense Responses.

    Kim, ByungHyun / Jiang, TingTing / Bae, Jun-Hyun / Yun, Hye Su / Jang, Seong Han / Kim, Jung Hyun / Kim, Jae Deog / Hur, Jin-Hoe / Shibata, Kensuke / Kurokawa, Kenji / Jung, Yunjin / Peschel, Andreas / Bae, Taeok / Lee, Bok Luel

    Infection and immunity

    2019  Band 87, Heft 12

    Abstract: Upon microbial infection, host immune cells recognize bacterial cell envelope components through cognate receptors. Although bacterial cell envelope components function as innate immune molecules, the role of the physical state of the bacterial cell ... ...

    Abstract Upon microbial infection, host immune cells recognize bacterial cell envelope components through cognate receptors. Although bacterial cell envelope components function as innate immune molecules, the role of the physical state of the bacterial cell envelope (i.e., particulate versus soluble) in host immune activation has not been clearly defined. Here, using two different forms of the staphylococcal cell envelope of
    Mesh-Begriff(e) Animals ; Cell Wall/immunology ; Chemokine CCL2/metabolism ; Chemokine CXCL1/metabolism ; Female ; Immunity, Innate/immunology ; Leukocyte L1 Antigen Complex/metabolism ; Macrophages/immunology ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Knockout ; Monocytes/immunology ; Neutrophils/immunology ; Phagocytosis/immunology ; Staphylococcal Infections/immunology ; Staphylococcal Infections/microbiology ; Staphylococcus aureus/immunology
    Chemische Substanzen Ccl2 protein, mouse ; Chemokine CCL2 ; Chemokine CXCL1 ; Cxcl1 protein, mouse ; Leukocyte L1 Antigen Complex
    Sprache Englisch
    Erscheinungsdatum 2019-11-18
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218698-6
    ISSN 1098-5522 ; 0019-9567
    ISSN (online) 1098-5522
    ISSN 0019-9567
    DOI 10.1128/IAI.00674-19
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang